288 related articles for article (PubMed ID: 11314018)
1. The TEL-Jak2 oncoprotein induces Socs1 expression and altered cytokine response in Ba/F3 cells.
Monni R; Santos SC; Mauchauffe M; Berger R; Ghysdael J; Gouilleux F; Gisselbrecht S; Bernard O; Penard-Lacronique V
Oncogene; 2001 Feb; 20(7):849-58. PubMed ID: 11314018
[TBL] [Abstract][Full Text] [Related]
2. Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation.
Frantsve J; Schwaller J; Sternberg DW; Kutok J; Gilliland DG
Mol Cell Biol; 2001 May; 21(10):3547-57. PubMed ID: 11313480
[TBL] [Abstract][Full Text] [Related]
3. The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2.
Kamizono S; Hanada T; Yasukawa H; Minoguchi S; Kato R; Minoguchi M; Hattori K; Hatakeyama S; Yada M; Morita S; Kitamura T; Kato H; Nakayama Ki ; Yoshimura A
J Biol Chem; 2001 Apr; 276(16):12530-8. PubMed ID: 11278610
[TBL] [Abstract][Full Text] [Related]
4. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells.
Lacronique V; Boureux A; Monni R; Dumon S; Mauchauffé M; Mayeux P; Gouilleux F; Berger R; Gisselbrecht S; Ghysdael J; Bernard OA
Blood; 2000 Mar; 95(6):2076-83. PubMed ID: 10706877
[TBL] [Abstract][Full Text] [Related]
5. Role of the cytokine-inducible SH2 protein CIS in desensitization of STAT5b signaling by continuous growth hormone.
Ram PA; Waxman DJ
J Biol Chem; 2000 Dec; 275(50):39487-96. PubMed ID: 10991939
[TBL] [Abstract][Full Text] [Related]
6. The tumor suppressor activity of SOCS-1.
Rottapel R; Ilangumaran S; Neale C; La Rose J; Ho JM; Nguyen MH; Barber D; Dubreuil P; de Sepulveda P
Oncogene; 2002 Jun; 21(28):4351-62. PubMed ID: 12080466
[TBL] [Abstract][Full Text] [Related]
7. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.
Lacronique V; Boureux A; Valle VD; Poirel H; Quang CT; Mauchauffé M; Berthou C; Lessard M; Berger R; Ghysdael J; Bernard OA
Science; 1997 Nov; 278(5341):1309-12. PubMed ID: 9360930
[TBL] [Abstract][Full Text] [Related]
8. Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells.
Spiekermann K; Pau M; Schwab R; Schmieja K; Franzrahe S; Hiddemann W
Exp Hematol; 2002 Mar; 30(3):262-71. PubMed ID: 11882364
[TBL] [Abstract][Full Text] [Related]
9. Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1.
Ungureanu D; Saharinen P; Junttila I; Hilton DJ; Silvennoinen O
Mol Cell Biol; 2002 May; 22(10):3316-26. PubMed ID: 11971965
[TBL] [Abstract][Full Text] [Related]
10. Constitutively active STAT5 variants induce growth and survival of hematopoietic cells through a PI 3-kinase/Akt dependent pathway.
Santos SC; Lacronique V; Bouchaert I; Monni R; Bernard O; Gisselbrecht S; Gouilleux F
Oncogene; 2001 Apr; 20(17):2080-90. PubMed ID: 11360192
[TBL] [Abstract][Full Text] [Related]
11. Modulation of Janus kinase 2 by cisplatin in cancer cells.
Song H; Sondak VK; Barber DL; Reid TJ; Lin J
Int J Oncol; 2004 Apr; 24(4):1017-26. PubMed ID: 15010843
[TBL] [Abstract][Full Text] [Related]
12. Endoplasmic reticulum stress prolongs GH-induced Janus kinase (JAK2)/signal transducer and activator of transcription (STAT5) signaling pathway.
Flores-Morales A; Fernández L; Rico-Bautista E; Umana A; Negrín C; Zhang JG; Norstedt G
Mol Endocrinol; 2001 Sep; 15(9):1471-83. PubMed ID: 11518796
[TBL] [Abstract][Full Text] [Related]
13. TEL-Syk fusion constitutively activates PI3-K/Akt, MAPK and JAK2-independent STAT5 signal pathways.
Kanie T; Abe A; Matsuda T; Kuno Y; Towatari M; Yamamoto T; Saito H; Emi N; Naoe T
Leukemia; 2004 Mar; 18(3):548-55. PubMed ID: 14749700
[TBL] [Abstract][Full Text] [Related]
14. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation.
Zhang JG; Farley A; Nicholson SE; Willson TA; Zugaro LM; Simpson RJ; Moritz RL; Cary D; Richardson R; Hausmann G; Kile BT; Kent SB; Alexander WS; Metcalf D; Hilton DJ; Nicola NA; Baca M
Proc Natl Acad Sci U S A; 1999 Mar; 96(5):2071-6. PubMed ID: 10051596
[TBL] [Abstract][Full Text] [Related]
15. Cytokine-inducible SH2-containing protein suppresses PRL signaling by binding the PRL receptor.
Dif F; Saunier E; Demeneix B; Kelly PA; Edery M
Endocrinology; 2001 Dec; 142(12):5286-93. PubMed ID: 11713228
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous activation of JAK1 and JAK2 confers IL-3 independent growth on Ba/F3 pro-B cells.
Huang HM; Lin YL; Chen CH; Chang TW
J Cell Biochem; 2005 Oct; 96(2):361-75. PubMed ID: 15988755
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor.
Bousquet C; Susini C; Melmed S
J Clin Invest; 1999 Nov; 104(9):1277-85. PubMed ID: 10545526
[TBL] [Abstract][Full Text] [Related]
18. Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling.
Ho JM; Beattie BK; Squire JA; Frank DA; Barber DL
Blood; 1999 Jun; 93(12):4354-64. PubMed ID: 10361134
[TBL] [Abstract][Full Text] [Related]
19. TEL-JAK2 constitutively activates the extracellular signal-regulated kinase (ERK), stress-activated protein/Jun kinase (SAPK/JNK), and p38 signaling pathways.
Ho JM; Nguyen MH; Dierov JK; Badger KM; Beattie BK; Tartaro P; Haq R; Zanke BW; Carroll MP; Barber DL
Blood; 2002 Aug; 100(4):1438-48. PubMed ID: 12149229
[TBL] [Abstract][Full Text] [Related]
20. Involvement of the NF-kappaB pathway in the transforming properties of the TEL-Jak2 leukemogenic fusion protein.
Santos SC; Monni R; Bouchaert I; Bernard O; Gisselbrecht S; Gouilleux F; Penard-Lacronique V
FEBS Lett; 2001 May; 497(2-3):148-52. PubMed ID: 11377430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
